In short
Irinotecan Hydrochloride, a chemotherapy drug, is being extensively studied in clinical trials for its potential in treating various types of cancer. These trials aim to evaluate its efficacy, safety, and optimal dosing when used alone or in combination with other drugs. The research spans across different cancer types, including solid tumors, brain metastases, and gastrointestinal cancers, offering hope for patients with hard-to-treat or advanced stage cancers.
At a glance
- Drug Name
- Irinotecan Hydrochloride
- Drug Class
- Topoisomerase I inhibitor
- Administration
- Intravenous (IV)
- Cancer Types Studied
- Solid tumors, brain metastases, esophageal, stomach, breast, biliary tract
- Combination Therapies
- Erlotinib hydrochloride, trifluridine/tipiracil
- Key Objectives
- Efficacy, safety, optimal dosing, pharmacokinetics
- Common Side Effects
- Diarrhea, nausea, vomiting, fatigue, decreased blood cell counts
- Outcome Measures
- Progression-free survival, overall survival, tumor response rates
What is Irinotecan Hydrochloride?
Irinotecan Hydrochloride, also known by brand names such as Camptosar, Campto, or CPT-11, is a chemotherapy drug used to treat various types of cancer. It belongs to a class of medications called topoisomerase I inhibitors, which work by interfering with the DNA replication of cancer cells, ultimately stopping their growth and division.
What Conditions Does Irinotecan Treat?
Irinotecan is primarily used to treat several types of cancer, including:
- Metastatic Colorectal Cancer: This is cancer that has spread from the colon or rectum to other parts of the body.
- Advanced Solid Tumors: These are cancers that form solid masses in various parts of the body.
- Brain and Central Nervous System Tumors: Specifically, it has been studied in the treatment of glioblastoma multiforme, an aggressive type of brain cancer.
- Non-Small Cell Lung Cancer: This is a type of lung cancer that accounts for most lung cancer cases.
How is Irinotecan Administered?
Irinotecan is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency can vary depending on the specific condition being treated and the patient's individual factors. Some common administration schedules include:
- 180 mg/m² given every 2 weeks
- 350 or 700 mg/m² given every 3 weeks
- 125 mg/m² given on days 1, 8, 15, and 22 of a 6-week cycle
The duration of each infusion is typically around 90 minutes. Your healthcare provider will determine the most appropriate dosage and schedule for your specific situation.
Irinotecan in Combination Therapies
Irinotecan is often used in combination with other cancer treatments to enhance its effectiveness. Some common combination therapies include:
- Irinotecan with Cetuximab: This combination is used in treating metastatic colorectal cancer, especially in patients who have previously responded to cetuximab-containing therapy.
- Irinotecan with Thalidomide: This combination has been studied for treating glioblastoma multiforme after radiation therapy.
- FOLFOXIRI plus Bevacizumab: This regimen combines irinotecan with oxaliplatin, 5-fluorouracil, leucovorin, and bevacizumab for treating metastatic colorectal cancer.
- Irinotecan with Temozolomide: This combination has been studied for treating recurrent glioblastoma.
Potential Side Effects
Like all chemotherapy drugs, irinotecan can cause side effects. Some potential side effects include:
- Neutropenia: A decrease in white blood cells, which can increase the risk of infections.
- Diarrhea: This can be severe and may require treatment.
- Nausea and vomiting.
- Fatigue
- Hair loss
- Anemia: A decrease in red blood cells, which can cause fatigue.
Your healthcare team will monitor you closely for these side effects and can provide treatments to help manage them.
Ongoing Research and Clinical Trials
Researchers continue to study irinotecan to find new ways to use it effectively and to improve patient outcomes. Some areas of ongoing research include:
- Using irinotecan in combination with newer targeted therapies.
- Studying the effectiveness of irinotecan in treating specific genetic subtypes of cancer.
- Investigating the use of irinotecan in perioperative treatment (treatment given before and after surgery) for colorectal cancer liver metastases.
- Exploring different dosing schedules to improve efficacy and reduce side effects.
If you're interested in participating in a clinical trial involving irinotecan, talk to your oncologist about potential opportunities.